These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466 [TBL] [Abstract][Full Text] [Related]
3. In vivo effects of thymostimulin treatment on monocyte polarization, dendritic cell clustering and serum p15E-like trans-membrane factors in operable head and neck squamous cell carcinoma patients. Kerrebijn JD; Simons PJ; Tas M; Balm AJ; Drexhage HA Eur Arch Otorhinolaryngol; 1995; 252(7):409-16. PubMed ID: 8562036 [TBL] [Abstract][Full Text] [Related]
4. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326 [TBL] [Abstract][Full Text] [Related]
5. Thymostimulin treatment in cases of AIDS and ARC. Raise E; Bonazzi L; Di Giandomenico G; Sabbatini S; Schiattone ML; Di Pede B; Gallo R; Savoia M; Martuzzi M J Exp Pathol; 1987; 3(4):745-50. PubMed ID: 3454812 [No Abstract] [Full Text] [Related]
6. A double-blind placebo-controlled study of thymostimulin (TP-1) for the treatment of atopic eczema. Harper JI; Mason UA; White TR; Staughton RC; Hobbs JR Br J Dermatol; 1991 Oct; 125(4):368-72. PubMed ID: 1835403 [TBL] [Abstract][Full Text] [Related]
7. Thymostimulin treatment in AIDS-related complex. Palmisano L; Chisesi T; Galli M; Gritti FM; Ielasi G; Lazzarin A; Mezzaroma I; Moroni M; Raise E; Vaglia A Clin Immunol Immunopathol; 1988 Jun; 47(3):253-61. PubMed ID: 3259480 [TBL] [Abstract][Full Text] [Related]
8. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma. Kerrebijn JD; Simons PJ; Balm AJ; Tas M; Knegt PP; de Vries N; Tan IB; Drexhage HA Head Neck; 1996; 18(4):335-42. PubMed ID: 8780944 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group. Cooper DA; Pehrson PO; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B AIDS; 1993 Feb; 7(2):197-207. PubMed ID: 8096703 [TBL] [Abstract][Full Text] [Related]
10. Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex. A multicenter, double-blind, placebo-controlled trial. Gottlieb MS; Zackin RA; Fiala M; Henry DH; Marcel AJ; Combs KL; Vieira J; Liebman HA; Cone LA; Hillman KS Ann Intern Med; 1991 Jul; 115(2):84-91. PubMed ID: 1676251 [TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndrome. Chachoua A; Green MD; Valentine F; Muggia FM Cancer Invest; 1989; 7(3):225-9. PubMed ID: 2790539 [TBL] [Abstract][Full Text] [Related]
12. [Effect of thymostimulin on endocrine thymus function in thyroidectomized rats during suppressive hormone therapy]. Hrinevych IuIa; Bendiuh HD; Ostapenko OM Fiziol Zh (1994); 2003; 49(6):43-6. PubMed ID: 14965037 [TBL] [Abstract][Full Text] [Related]
13. The effects of thymostimulin on immunological function in patients with head and neck cancer. Kerrebijn JD; Simons PJ; Tas M; Knegt PP; Van de Brekel MW; Delaere P; Tan IB; Drexhage HA; Balm AJ Clin Otolaryngol Allied Sci; 1996 Oct; 21(5):455-62. PubMed ID: 8932953 [TBL] [Abstract][Full Text] [Related]
14. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356 [TBL] [Abstract][Full Text] [Related]
15. Thymostimulin in the treatment of hepatitis B surface antigen-positive chronic active hepatitis. Controlled clinical trial--two years follow-up. Romeo F; Palmisano L; Arcoria D Arzneimittelforschung; 1987 Apr; 37(4):450-6. PubMed ID: 3300664 [TBL] [Abstract][Full Text] [Related]
16. [Postoperative infections: the use of thymostimulin (TP1) in patients at risk]. Lai N; Lavosi V; Pinna S; Salis G; Colombo E; Vargiu P G Chir; 1992; 13(6-7):377-8. PubMed ID: 1389989 [TBL] [Abstract][Full Text] [Related]
17. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of thymostimulin. Bertarelli F Lancet; 1994 Jan; 343(8890):184. PubMed ID: 7904038 [No Abstract] [Full Text] [Related]
19. [Therapeutic use of thymostimulin in HIV-seropositive subjects and with lymphadenopathy syndrome]. Carcò F; Guazzotti G Recenti Prog Med; 1993 Nov; 84(11):756-64. PubMed ID: 8290787 [TBL] [Abstract][Full Text] [Related]